3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions

US7495002B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Elke Langkopf · Biberach an der Riß, DE
• Matthias Eckhardt · Hannover, DE
• Frank Himmelsbach · Mittelbiberach, DE
• Mohammad Tadayyon · Hertford, GB
• Leo Thomas · Biberach, DE
• Ralf Lotz · Schemmerhofen, DE

Key dates

• Filing date: Sep 1, 2005
• Grant date: Feb 24, 2009
• Expiry date: Oct 22, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to new substituted xanthines of general formulawherein R1, R2 and X are defined as in the claims, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).